Key statistics dashboard for Lantern Pharma Inc. (LTRN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer.
Stock Data
| Price | $1.93 |
| Market Cap | $25M |
| Beta | 1.75 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.05 |
| Price / Book | -6.56 |
| P/S | 0.00 |
| P/FCF | -1.54 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 1.96 |
| Quick Ratio | 1.96 |
| Cash Ratio | 1.54 |
| Debt / Equity | -0.01 |
| Debt / Assets | 0.46% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | -0.26 |
| Cash per share | 0.59 |
| FCF per share | -1.13 |
| Tangible Book Value per share | -0.26 |
| Dividend per share | 0.00 |
Related companies: ANVS · ATNM · BCAB · CALC · ELUT · LVTX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of LTRN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks